Reprint
Diagnostics, Risk Factors, Treatment and Outcomes of Acute Kidney Injury in a New Paradigm
Edited by
July 2020
574 pages
- ISBN978-3-03936-086-4 (Hardback)
- ISBN978-3-03936-087-1 (PDF)
This is a Reprint of the Special Issue Diagnostics, Risk Factors, Treatment and Outcomes of Acute Kidney Injury in a New Paradigm that was published in
Medicine & Pharmacology
Public Health & Healthcare
Summary
Acute kidney injury (AKI) is a frequent clinical syndrome among hospitalized patients, independently associated with both short- and long-term mortality. Previous investigations attempted to identify effective interventions to prevent AKI or promote kidney function recovery in patients with AKI. Most were unsuccessful. Hence, additional studies are required in the field of AKI research. In this Special Issue, we are making a call to action to stimulate researchers and clinicians to submit their studies on AKI conducted in nephrology, internal medicine, critical care, and other disciplines that will provide additional knowledge and skills in the field of AKI research, ultimately to improve patient outcomes.
Format
- Hardback
License and Copyright
© 2020 by the authors; CC BY-NC-ND license
Keywords
acute kidney injury; biomarker; fibroblast growth factor-23; kidney injury molecule-1; mortality; neutrophil gelatinase-associated lipocalin; renal replacement therapy; acute kidney injury; Cockcroft Gault; Jelliffe; MDRD; drug dosing; antimicrobials; acute kidney injury; chronic obstructive pulmonary disease; congestive heart failure; stroke; acute kidney injury; adverse cardiovascular events; atrial fibrillation; dialysis; critical care; vasoactive agents; norepinephrine; sepsis; acute kidney injury; dialysis; acute kidney injury; definition; incidence; classification; acute kidney injury; patient safety; hemodialysis; acute kidney injury; cardiovascular surgery; machine learning; continuous renal replacement therapy; early mortality; clinical illness; albuminuria; chloride; postoperative acute kidney injury; cardiac surgery; biomarkers; right heart failure; congestive acute kidney injury; venous congestion; septic shock; acute kidney injury; acute kidney disease; chronic kidney disease; follow-up; acute kidney injury; statins; chronic kidney disease; acute kidney injury; urine output; hemodynamics; living-donor liver transplantation; acute kidney injury; acute renal failure; hip arthroplasty; hip Surgery; postoperative acute kidney injury; incidence; epidemiology; systematic reviews; meta-analysis; urine calprotectin; acute kidney injury; intrinsic renal injury; acute kidney injury; myocardial infarction; ischemia; biomarkers; management; diversity outcome; acute kidney injury; genetic variation; human genetics; Acute renal failure; Acute kidney injury; Epidemiology; Incidence; Meta-analysis; Liver Transplantation; Transplantation; Systematic reviews; acute kidney injury; critical care; intensive care units; diabetes mellitus; acute kidney injury; nephrectomy; minimally invasive surgical procedures; risk factors; acute kidney injury; anesthetic technique; total knee arthroplasty; vancomycin; MRSA; nephrotoxicity; acute kidney injury; piperacillin-tazobactam; creatinine; KIM-1; AKIN; KDIGO; RIFLE; acute kidney injury; infective endocarditis; healthcare costs; opioid use; acute kidney injury; AKI; extracorporeal membrane oxygenation; ECMO; epidemiology; meta-analysis; uric acid; contrast media; acute kidney injury; hemodialysis; chronic kidney disease; post-operative complications; acute kidney injury; enhanced recovery; goal directed therapy; emergency surgery; laparotomy; acute kidney injury; chronic kidney disease; AKI staging; acute kidney injury; in-hospital mortality; comorbidity; International Classification of Diseases; 9th Revision; Clinical Modification (ICD-9-CM); acute kidney injury; partial nephrectomy; parenchymal mass reduction; ischemia; nephrectomy; acute kidney injury; chronic kidney disease; sevoflurane; desflurane; propofol; acute kidney injury; incidence; lung transplantation; transplantation; epidemiology; meta-analysis; Sepsis-3; acute dialysis; qSOFA; acute kidney injury; acute kidney injury; cardiovascular surgery; ICU; complications; biomarkers; acute kidney injury; acute tubular necrosis; TRPA1; recovery of renal function; acute kidney injury; critically ill patients; renal recovery; chronic kidney disease; end stage renal disease; cardiovascular surgical intensive care units; cardiac surgery; acute kidney injury; cyclophilin A; neutrophil gelatinase-associated lipocalin; continuous renal replacement therapy (CRRT); specialized CRRT team (SCT); retrospective study; sepsis-induced AKI; advanced hemodynamic monitoring; beta-trace protein; cystatin C; acute pancreatitis; severity; acute kidney injury; acute kidney injury; acute renal failure; biomarkers; critical care; renal replacement therapy; risk factors outcomes; predictors